<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/25463114-D1A9-45A7-A84B-7F19B424B6C8"><gtr:id>25463114-D1A9-45A7-A84B-7F19B424B6C8</gtr:id><gtr:name>Cyclacel Ltd</gtr:name><gtr:address><gtr:line1>6-8 Underwood Street</gtr:line1><gtr:city>London</gtr:city><gtr:postCode>N1 7JQ</gtr:postCode><gtr:region>London</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/AE58F21F-3622-4382-97BB-1359BD183E9F"><gtr:id>AE58F21F-3622-4382-97BB-1359BD183E9F</gtr:id><gtr:name>University of Glasgow</gtr:name><gtr:address><gtr:line1>University Avenue</gtr:line1><gtr:line4>Glasgow</gtr:line4><gtr:postCode>G12 8QQ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/5E2B04DD-4A03-45ED-9892-61C5CCB8AC68"><gtr:id>5E2B04DD-4A03-45ED-9892-61C5CCB8AC68</gtr:id><gtr:name>Newcastle University</gtr:name><gtr:department>Institute of Cellular Medicine</gtr:department><gtr:address><gtr:line1>1 Park Terrace</gtr:line1><gtr:line4>Newcastle Upon Tyne</gtr:line4><gtr:line5>Tyne and Wear</gtr:line5><gtr:postCode>NE1 7RU</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5E2B04DD-4A03-45ED-9892-61C5CCB8AC68"><gtr:id>5E2B04DD-4A03-45ED-9892-61C5CCB8AC68</gtr:id><gtr:name>Newcastle University</gtr:name><gtr:address><gtr:line1>1 Park Terrace</gtr:line1><gtr:line4>Newcastle Upon Tyne</gtr:line4><gtr:line5>Tyne and Wear</gtr:line5><gtr:postCode>NE1 7RU</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/25463114-D1A9-45A7-A84B-7F19B424B6C8"><gtr:id>25463114-D1A9-45A7-A84B-7F19B424B6C8</gtr:id><gtr:name>Cyclacel Ltd</gtr:name><gtr:address><gtr:line1>6-8 Underwood Street</gtr:line1><gtr:city>London</gtr:city><gtr:postCode>N1 7JQ</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/AE58F21F-3622-4382-97BB-1359BD183E9F"><gtr:id>AE58F21F-3622-4382-97BB-1359BD183E9F</gtr:id><gtr:name>University of Glasgow</gtr:name><gtr:address><gtr:line1>University Avenue</gtr:line1><gtr:line4>Glasgow</gtr:line4><gtr:postCode>G12 8QQ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/EEE5331C-7D11-4578-BAC5-788C990A6C47"><gtr:id>EEE5331C-7D11-4578-BAC5-788C990A6C47</gtr:id><gtr:firstName>Iain</gtr:firstName><gtr:surname>McInnes</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/16B653E2-0DEA-4EC3-BEB0-B755754726BD"><gtr:id>16B653E2-0DEA-4EC3-BEB0-B755754726BD</gtr:id><gtr:firstName>Christopher</gtr:firstName><gtr:surname>Buckley</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/B15AA0FD-FA49-49BE-A7A0-6641BD564386"><gtr:id>B15AA0FD-FA49-49BE-A7A0-6641BD564386</gtr:id><gtr:firstName>Chris</gtr:firstName><gtr:surname>Speed</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/B8337C44-7C9D-4E5C-9D4B-EC284605F8E2"><gtr:id>B8337C44-7C9D-4E5C-9D4B-EC284605F8E2</gtr:id><gtr:firstName>Wan-Fai</gtr:firstName><gtr:surname>Ng</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/77B2189C-07F0-4EBA-A2A5-A58AD53ECF78"><gtr:id>77B2189C-07F0-4EBA-A2A5-A58AD53ECF78</gtr:id><gtr:firstName>Deborah</gtr:firstName><gtr:surname>Stocken</gtr:surname><gtr:orcidId>0000-0001-8031-1738</gtr:orcidId><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/C14FA61D-EC5E-40A0-ACB9-D757FEABC8E5"><gtr:id>C14FA61D-EC5E-40A0-ACB9-D757FEABC8E5</gtr:id><gtr:firstName>Andrew</gtr:firstName><gtr:surname>Filer</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/A33E8994-FD55-40AD-BF5D-31CD2B770EE2"><gtr:id>A33E8994-FD55-40AD-BF5D-31CD2B770EE2</gtr:id><gtr:firstName>Stefan</gtr:firstName><gtr:surname>Siebert</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/57A37958-62F0-4123-94F1-B401A3343848"><gtr:id>57A37958-62F0-4123-94F1-B401A3343848</gtr:id><gtr:firstName>John</gtr:firstName><gtr:otherNames>Dudley</gtr:otherNames><gtr:surname>Isaacs</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MR%2FL005123%2F1"><gtr:id>E72B19E1-49F1-4AA9-8635-61D70D6DE5BF</gtr:id><gtr:title>MICA: Targeting the RA synovial fibroblast via cyclin dependent kinase inhibition - a phase IIa study</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>MR/L005123/1</gtr:grantReference><gtr:abstractText>Context 
Rheumatoid arthritis (RA) is a condition in which the joints become inflamed and painful. It affects about 1 in every 100 adults in the UK. It is thought to be caused by the patient's immune system mistakenly attacking their joints. The resulting inflammation is not only painful but reduces joint movement and eventually causes joint damage and deformity. RA can also affect other organs such as the lungs, and patients with RA also have a higher than average risk of developing heart attacks and strokes. They are also more susceptible to infections. Many patients lose their jobs soon after the diagnosis is made.

Aims and objectives
Most drugs currently used to treat RA neutralise the inflammation (anti-inflammatory drugs, steroids) or the cells of the immune system and their products (biological therapies or 'magic bullets'). Over the past 20 years the outcome for RA patients has improved, partly because of earlier and more 'aggressive' treatment (more drugs, higher doses) and partly because of new therapies that have been developed (particularly the 'magic bullets'). However, many patients don't respond completely to these treatments and some don't respond at all. We believe that there is another type of cell responsible for the symptoms in these patients. The fibroblast is a cell that is present in healthy joints, where it is important for normal joint function. However, fibroblasts divide inappropriately and become more numerous and 'aggressive' in RA joints. They damage the joint by producing chemicals that eat into cartilage and bone, and also produce inflammatory chemicals themselves. 

Thus, a useful cell in health becomes one that causes inflammation and joint damage in RA. As far as we know none of the current treatments affect the behaviour of fibroblasts. Our plan is test a drug in RA patients that we think will do so. The drug interferes with the machinery that is necessary for cells to divide. Fibroblasts in the RA joint seem particularly sensitive to this drug, which we therefore believe can correct their abnormal behaviour. The drug has already been tested in patients with certain types of cancer (in which cells also divide inappropriately) and seems safe enough to test in RA. We aim to show that the treatment is safe in RA, and that it could provide a useful treatment for RA patients. 

The research is divided into two parts. In the first part we will test the safety of different doses of the drug over 4 weeks of treatment. We will identify a dose that is both safe and appropriate to test in more patients for a longer period of time. In the second part we will give this dose to 12 RA patients for 12 weeks. At the same time 6 patients will receive an identical 'placebo' treatment. This is important to ensure that any effects we see are due to the drug and not other factors (more visits to the hospital, more interaction with doctors and nurses). As well as checking the patients' symptoms, we will also perform scans of their joints at the start and end of the treatment. We will also take small samples of joint tissue (biopsies). These scans and biopsies will help us to decide whether the treatment is working and how it is working. This is important to help us to decide whether the trial has been a 'success' and whether to perform further trials later on. 

Potential applications and benefit
In this trial we will treat patients who have had RA for at least a year and who are already taking treatment but not responding well enough. This will test our idea that we can improve their symptoms by altering the behaviour of the fibroblasts. If this research is successful then we will need to test the treatment in RA patients taking different treatments, at different stages of their illness. Because this treatment works in such a different way to existing drugs, we believe it could be useful for many different types of RA patient. Later on, if safe and effective, it may also be useful in other diseases.</gtr:abstractText><gtr:technicalSummary>This project aims to repurpose a small molecule anti-cancer drug as an anti-fibroblast drug for RA. The past 20 years have seen major advances in RA therapy; more aggressive use of conventional drugs, and biological targeted therapies have each made a significant impact. However, disease remission remains uncommon and around 20% of patients remain refractory to all therapies. This represents a significant unmet need and suggests key aspects of RA pathogenesis remain untargetted.
In health, a delicate nutritive synovial membrane (SM) lines joint cavities. This comprises a few macrophages and fibroblasts in a loose connective tissue stroma. In RA the SM is the focus of autoimmune attack but, in addition to inflammatory cell infiltration, resident synovial fibroblasts (SF) become hyperplastic, forming a vascularised, inflammatory, quasi-malignant pannus which invades articular cartilage and bone. The resultant joint damage underlies the disability and reduced quality of life that characterise RA.
Cell proliferation relies on the coordinated activation of specific regulatory proteins: orderly progression through the cell cycle is tightly controlled by the formation and activation of complexes comprising cyclin proteins and cyclin-dependent kinases (CDK). These complexes are in turn regulated by endogenous CDK inhibitors (CDKI). The concept of inhibiting CDKs to correct uncontrolled cell proliferation has led to the evaluation of small molecule CDKI in cancer.
RA SF have reduced endogenous CDKI levels, and correction of the deficit normalises their dysregulated phenotype. Indeed, small molecule CDKI ameliorate synovitis in pre-clinical arthritis models. In partnership with the SME Cyclacel, we propose a phase IIa repurposing study of a CDKI in patients with refractory RA. Stage 1 will focus on safety and tolerability, to determine an appropriate dose to progress to stage 2, where we will seek evidence of potential therapeutic activity alongside PK and PD biomarkers.</gtr:technicalSummary><gtr:potentialImpactText>Our research aims to deliver a new drug and a novel therapeutic approach, therefore potential beneficiaries include patients, the NHS, the life sciences industry, UK plc, Arthritis Research UK and other funders, the project team and other academic researchers.
Patients with RA will derive the most immediate impact from our research, which could provide a novel therapy with a unique mechanism of action. This could result in better disease control, improved quality of life and reduced long-term complications, either as a monotherapy or in combination with existing drugs. Success will also stimulate research into related compounds from the same class as well as alternative anti-fibroblast drugs and targets (eg pro-apoptosis, epigenetic modifiers, anti-proliferative). It will also stimulate research into potential applications in other fibrotic diseases - all with potential downstream beneficial impact on patients. Via our Engagement programmes this work will have a wider impact on patients by reinforcing the benefits of participating in early phase experimental medicine research.
For similar reasons success will provide a boost to the UK life sciences industry. Clearly our Partner would benefit greatly but so too will other SMEs, biotechs, and pharma with alternative drugs from the same class, as well as drugs with the potential to target the fibroblast in a distinct manner. Our research would provide a novel target and a novel paradigm for the treatment of RA and would also trigger a re-analysis of exisiting compounds that may have therapeutic potential in RA or, indeed, other fibrotic diseases. RA remains a disease with a high unmet need and provides potentially high investment returns. Some of the other potential disease targets could become 'orphan' indications, with a more commercially favourable path to the clinic. 
Downstream success will lead to a workforce with an improved skill set, including UK/EU contract manufacturing capabilities, and specialist PK testing. Ultimately successful development of a novel drug for RA will deliver substantial revenue to the UK and catalyse additional activity in the healthcare sector. It will also impact on HM Government by reinforcing the benefits of their investment in the life sciences industry. 
We are using UK based companies for sub-contracted work. This will have a positive impact on income generated and jobs protected within home countries.
Because our research involves an orally available drug, it would likely be cheaper than the biologic drugs. If it substituted for them in the treatment pathway, or improved their efficacy as hypothesised, this would ultimately result in direct or indirect cost-savings to the NHS.
In addition to the MRC, Arthritis Research UK, NIHR, the Wellcome Trust, the partner Universities and NHS Trusts will benefit from our research, because they are providing some of the infrastructure and staff needed to perform this research. They would therefore be in a position to share in the success. The development of a new drug for RA would likely lead to an increase in charitable donations to relevant charities.
Success will impact on the project team both directly, via the experience and educational opportunities of performing a successful phase II experimental medicine study; and also indirectly from the emotional and psychological benefits of involvement with a study that could potentially benefit thousands of patients. 
Lastly, other academic researchers will clearly derive impact from this research, which will provide them directly with new ideas and opportunities, and indirectly by increasing collaborative opportunities with one another and with the life sciences sector.</gtr:potentialImpactText><gtr:fund><gtr:end>2019-09-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2014-03-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>1126733</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Glasgow</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Rheumatology</gtr:department><gtr:description>Cyclacel</gtr:description><gtr:id>CBF27CB8-7625-4DA3-95CB-A9B0D8AAD858</gtr:id><gtr:impact>MRC DPFS/DCS grant for &amp;pound;1.1m</gtr:impact><gtr:outcomeId>sdhWiJRFyHJ-2</gtr:outcomeId><gtr:partnerContribution>Cyclacel are providing drug and also support in kind for the research.
Glasgow and Birmingham are collaborating with us on the research - recruiting patients, performing biomarker measurements</gtr:partnerContribution><gtr:piContribution>We have written a successful MRC MICA grant to repurpose an anti-proliferative drug in rheumatoid arthritis patients</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Birmingham</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Rheumatology Research Group</gtr:department><gtr:description>Cyclacel</gtr:description><gtr:id>CB680772-4629-4BB0-8D71-F4136AD3E9F4</gtr:id><gtr:impact>MRC DPFS/DCS grant for &amp;pound;1.1m</gtr:impact><gtr:outcomeId>sdhWiJRFyHJ-3</gtr:outcomeId><gtr:partnerContribution>Cyclacel are providing drug and also support in kind for the research.
Glasgow and Birmingham are collaborating with us on the research - recruiting patients, performing biomarker measurements</gtr:partnerContribution><gtr:piContribution>We have written a successful MRC MICA grant to repurpose an anti-proliferative drug in rheumatoid arthritis patients</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cyclacel Ltd</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Cyclacel</gtr:description><gtr:id>B5394937-0AE2-4F38-978E-7286A7FB99ED</gtr:id><gtr:impact>MRC DPFS/DCS grant for &amp;pound;1.1m</gtr:impact><gtr:outcomeId>sdhWiJRFyHJ-1</gtr:outcomeId><gtr:partnerContribution>Cyclacel are providing drug and also support in kind for the research.
Glasgow and Birmingham are collaborating with us on the research - recruiting patients, performing biomarker measurements</gtr:partnerContribution><gtr:piContribution>We have written a successful MRC MICA grant to repurpose an anti-proliferative drug in rheumatoid arthritis patients</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Birmingham</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>ARUK Centre of Excellence in rheumatoid arthritis pathogenesis</gtr:description><gtr:id>8F988E6C-710E-4712-BD1F-11EB2E27DDBB</gtr:id><gtr:impact>Research grant, valu &amp;pound;2.5m spread across the three centres</gtr:impact><gtr:outcomeId>RSfYaiCsVQR-2</gtr:outcomeId><gtr:partnerContribution>Each centre will provide a unique scientific contribution to the Centre</gtr:partnerContribution><gtr:piContribution>WE have written a successful funding application to Arthritis Research UK for a Centre of Excellence in RA pathogenesis, value &amp;pound;2.5m over five years</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Glasgow</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>ARUK Centre of Excellence in rheumatoid arthritis pathogenesis</gtr:description><gtr:id>A367178F-00EF-4FF6-A190-695940B57022</gtr:id><gtr:impact>Research grant, valu &amp;pound;2.5m spread across the three centres</gtr:impact><gtr:outcomeId>RSfYaiCsVQR-1</gtr:outcomeId><gtr:partnerContribution>Each centre will provide a unique scientific contribution to the Centre</gtr:partnerContribution><gtr:piContribution>WE have written a successful funding application to Arthritis Research UK for a Centre of Excellence in RA pathogenesis, value &amp;pound;2.5m over five years</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Zing Conference Spain</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>A7EFB515-AD20-4BB9-927B-8ACC369CCF93</gtr:id><gtr:impact>Prospective collaborations and partnerships</gtr:impact><gtr:outcomeId>56dff31edbdd47.46779601</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Dutch Rheumatology Days</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>BE8156C9-43B1-46B2-A533-C84B02039315</gtr:id><gtr:impact>Utrecht Rheumatology Workshop</gtr:impact><gtr:outcomeId>56dec2de3f6041.34207563</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>RACE Meeting Newcastle 2016</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>A3997B67-CB8B-4694-B9B5-63AD0A890B8E</gtr:id><gtr:impact>Planning for the ARUK 'cure' call.</gtr:impact><gtr:outcomeId>58bec16239a6e8.84594606</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>South African Immunology Meeting</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>148D07E6-F58B-40A0-A94A-53C8DC35BE6D</gtr:id><gtr:impact>University of Pretoria Basic Immunology and Immunology in RA.</gtr:impact><gtr:outcomeId>56dec36ab75dd7.89867712</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Great North Experimental Arthritis Treatment Centre website</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>248B441A-DC3D-4E8E-9843-CA65616DE2AE</gtr:id><gtr:impact>The activity is ongoing</gtr:impact><gtr:outcomeId>545e2ac8a70760.84616697</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:url>http://www.greatneatcentre.com/</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Central &amp; Eastern European Immunology Forum Bucharest 2016</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>3DCC64D3-BBCD-4D08-B68B-C4F6CE7E9310</gtr:id><gtr:impact>New Treatments for Immune Mediated Inflammatory Diseases</gtr:impact><gtr:outcomeId>58bd7105ca30e7.14986884</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>GSK Industry Engagement Visit Newcastle 2016</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>E5A9C3B1-6931-437E-A2E4-58914BDF5806</gtr:id><gtr:impact>Explored shared interests - potential for interaction - biopsy procedures</gtr:impact><gtr:outcomeId>58beb6e179f1e5.19903110</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Industry/Business</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>RACE Annual Review 2016 Birmingham</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>05545455-CC67-43F2-AD2D-9B0A26DBAB05</gtr:id><gtr:impact>Annual review chaired by Ann Cooke. Caroline Aylott and Craig Bullock. Re-aligned research focus for 2016-2017.</gtr:impact><gtr:outcomeId>58bebb48251002.39335091</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Targeted Therapies Meeting - Mallorca 2016</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>59747E6A-2945-4A90-8692-8525BFF54374</gtr:id><gtr:impact>Invite only meeting. Session chair.</gtr:impact><gtr:outcomeId>58bed0040e33b3.07306403</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Bones Exhibition Great North Museum 2017</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>7C4C98BF-9213-4388-A7C4-D0F63B8ADD6E</gtr:id><gtr:impact>Design input to Learning Zone activities supporting the Exhibition. Posters and public information leaflets.</gtr:impact><gtr:outcomeId>58c411723d15c1.45971287</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>https://greatnorthmuseum.org.uk/whats-on/bones-skeleton-secrets-of-the-animal-world</gtr:url><gtr:year>2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>OK To Ask</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>6BFE67FA-F703-4B06-A968-7F9B97CE7D8A</gtr:id><gtr:impact>Talks and poster sessions promoting participation in Newcastle Experimental Arthritis Treatment Centre. 

Generated questions, discussion and approaches from members of the public interested in participating in arthritis research.

Patients contacted Research Nurses enquiring about participation in research.</gtr:impact><gtr:outcomeId>556807615e3581.40195587</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:url>http://www.nihr.ac.uk/oktoask</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Refractory Rheumatoid Arthritis - York 2016</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>ACEC150F-F211-4290-AE4F-9436B4950F2F</gtr:id><gtr:impact>Keynote lecture on Refractory RA at the Northern group annual meeting</gtr:impact><gtr:outcomeId>58be8c5be30a86.76662191</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>RACE Scientific Advisory Board Meeting 2016</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>12DA1331-3C0A-415E-BE67-FCF55FB0FE0A</gtr:id><gtr:impact>Presentations on TRAFIC and BIO-FLARE as worked examples of our experimental medicine approach.</gtr:impact><gtr:outcomeId>58be8ae26d07c4.87680112</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>TEDx Newcastle</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>AE42FA3F-4585-444D-824D-44524E0EC21F</gtr:id><gtr:impact>It provided an opportunity to highlight the importance of patient participation in experimental medicine and translational research studies

The TEDx Newcastle website has received more than 10000 hits</gtr:impact><gtr:outcomeId>545e290d307c99.22664705</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.greatneatcentre.com/2014/07/the-patient-who-changed-my-life-people.html</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>RACE launch</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>4BE68C74-B6EE-4F81-ADE3-15E8D593C6A3</gtr:id><gtr:impact>Interesting discussions, including with an Olympian

None yet</gtr:impact><gtr:outcomeId>545e27acdae5a5.06466318</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Rheumatoid Arthritis Strategic Review, Newcastle, 2015</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>E23F0E6E-090E-49A4-AFC4-F630F2A2154A</gtr:id><gtr:impact>Strategic realignment of research activities</gtr:impact><gtr:outcomeId>56def87a138762.44807934</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>BT-CURE Workshop - Stockholm 2016</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>DEAC5521-FD39-4C67-9D7D-2D7FD8664795</gtr:id><gtr:impact>AuToDeCRA Lecture and RT-CURE IMI proposal</gtr:impact><gtr:outcomeId>58becb8825d5b3.47740139</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>9th International Symposium on Uveitis Dublin 2016</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>22ECA274-1D7D-4D26-8C4A-953534222422</gtr:id><gtr:impact>Lecture on Biologics in Rheumatology</gtr:impact><gtr:outcomeId>58beb305348bb1.68663691</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Newcastle Upon Tyne Hospitals - Rheumatoid Arthritis Where Next?</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>FF07F105-6855-4947-98A4-E958675230D5</gtr:id><gtr:impact>Presentation on future RA research directions to junior doctors and medical staff in the NUTH Trust</gtr:impact><gtr:outcomeId>58be88e29d4b86.39902421</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>UK Autoimmunity Workshop - Defining the Grand Challenges - Clinical Trials, New Therapeutics, Repurposing</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>8F1F2A0D-BA88-4CF7-82AF-A9DB810B0D70</gtr:id><gtr:impact>JDRF
MRC
ARUK
WT</gtr:impact><gtr:outcomeId>58beda21436a20.20679783</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>ARUK Arthritis Matters 2014</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>5C67E075-CE73-4E4F-BC4B-DE60A248F58D</gtr:id><gtr:impact>There was useful discussion after my presentation about the reach of charitable funding

Patients volunteered to join TRAFIC steering group</gtr:impact><gtr:outcomeId>545e26c3201d25.41640600</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.musculoskeletalresearch.com/2014/07/arthritis-matters-2014.html</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>MRC Research Strategy Visit 2016</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>07E948CC-7242-4995-B26E-148D0DE765DB</gtr:id><gtr:impact>Reviewed medical research at Newcastle highlighting achievements in experimental medicine and translational research and identifying improvement opportunities.</gtr:impact><gtr:outcomeId>58bd7411762905.36563473</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Supporters</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Research Engagement Poster Campaign 2015</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>F1F6612A-F023-4F15-83FE-00EAAF470B66</gtr:id><gtr:impact>Poster campaign describing research in lay terms for public and patients audience. To promote engagement in research in the NE.

Public and patients expressed interest in participating in research.</gtr:impact><gtr:outcomeId>55659ac7806849.25662274</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>&quot;Bones&quot; Exhibition at the Great North Museum 2017</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>20896AD3-4B3B-43C9-A98A-110FD8549309</gtr:id><gtr:impact>Workshops, demonstrations, talk, events and public information materials presented in parallel with the Bones Exhibition at the Great North Museum highlighting musculoskeletal research at our Centres of Excellence at Newcastle University including the Centre for Integrated Musculoskeletal Ageing, the Newcastle Experimental Arthritis Treatment Centre, the Rheumatoid Arthritis Centre of Excellence and the Newcastle Biomedical Research Centre.</gtr:impact><gtr:outcomeId>58bd5398c9bac6.09099676</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>https://greatnorthmuseum.org.uk/whats-on/bones-skeleton-secrets-of-the-animal-world</gtr:url><gtr:year>2017</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Novel Therapies in Rheumatoid Arthritis</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>345DEFA9-39EF-40A4-842C-7241F3361961</gtr:id><gtr:outcomeId>56dec13d1d8a85.13593749</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Arthritis Research UK Rare Diseases Workshop 2017</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>696A3BFA-B558-43CF-84AA-FF255CD6C5F0</gtr:id><gtr:outcomeId>58bd5ae00fc3f9.12459038</gtr:outcomeId><gtr:type>Participation in a national consultation</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>VGFyZ2V0aW5nIHRoZSBSQSBzeW5vdmlhbCBmaWJyb2JsYXN0IHZpYSBjeWNsaW4gZGVwZW5kZW50
IGtpbmFzZSBpbmhpYml0aW9uIMKWIC0gYW4gZWFybHkgcGhhc2UgdHJpYWwgKFRSQUZJQyk6IGEg
bm9uLXJhbmRvbWlzZWQgdHJpYWwuICBTaXRlIHNldC11cCBhdCB0aHJlZSBjZW50cmVzIGluIHRo
ZSBVSy4gIE91dHNvdXJjaW5nIG9mIFBLIHRvIENoYXJsZXMgUml2ZXIgYW5kIGNsaW5pY2FsIHRy
aWFsIHBhY2thZ2luZyBhY3Rpdml0aWVzIHRvIHRoaXJkIHBhcnR5Lg==</gtr:description><gtr:id>CAC3E1DE-6105-4FB8-B8A1-0D1861369855</gtr:id><gtr:impact>Recruitment of two additional sites.
First use of continuous reassessment modelling algorithm dose escalation study outside of oncology.</gtr:impact><gtr:outcomeId>58c96ace808863.13818916</gtr:outcomeId><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>TRAFIC:Targeting the RA synovial fibroblast via cyclin dependent kinase inhibition</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:url>http://www.isrctn.com/ISRCTN36667085?</gtr:url><gtr:yearDevCompleted>2013</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs><gtr:softwareAndTechnicalProductOutput><gtr:description>Software tool permitting continuous reassessment modelling algorithm to determine dose escalation allowing recruitment of patients to a complex trial across multiple collaborator sites.</gtr:description><gtr:id>E392625E-5D9D-4CE0-B213-E3D2DE7FEDD6</gtr:id><gtr:impact>May be of commercial interest.</gtr:impact><gtr:outcomeId>58c96c9b8e1558.06890982</gtr:outcomeId><gtr:title>COLLABORATOR In-House Software</gtr:title><gtr:type>Webtool/Application</gtr:type><gtr:yearFirstProvided>2017</gtr:yearFirstProvided></gtr:softwareAndTechnicalProductOutput></gtr:softwareAndTechnicalProductOutputs><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">MR/L005123/1</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>C6D70A71-8796-47BC-AFE0-CC2286E66A06</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Inflammatory and Immune System</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>7135039D-2DB0-4D41-87B3-FA1C8D38E133</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>6.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>